# DarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology

- Link: https://www.thailand-business-news.com/pr-news/darwinhealth-introduces-quantum-cancer-biology-a-cell-state-systems-biology-framework-for-precision-oncology
- Published: 2026-08-26T19:38:00+07:00
- Author: PR Newswire

|   |

**New paradigm integrates single-cell transcriptomics, regulatory network inference,
and AI to decode—and therapeutically target—the multiple, co-existing cancer cell
states that drive resistance in pancreatic cancer, glioblastoma, and other lethal
malignancies**

NEW YORK, Aug. 26, 2026 /PRNewswire/ — **DarwinHealth**, a New York-based, AI-centric
biotechnology company. today announced the introduction of **Quantum Cancer Biology:
A Cell-State Systems Biology Framework for Precision Oncology**, a transformative
scientific paradigm designed to address one of oncology’s greatest unsolved challenges:
why the world’s deadliest cancers continue to evade even the most advanced targeted
therapies.

The announcement accompanies the publication in **_Nature Genetics_** ([https://www.nature.com/articles/s41588-026-02714-8](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760010-1&h=711605373&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41588-026-02714-8&a=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41588-026-02714-8))
of a new perspective led by Dr. Andrea Califano and Dr. Kenneth P. Olive, driven
by first author Dr. Pasquale Laise, PhD, alongside co-first authors Mikko Turunen,
PhD, and Alvaro Curiel-Garcia, PhD.

The study, conducted at Columbia University, presents original research findings
and argues that the next revolution in oncology will not come from discovering a
single "miracle drug," but from longitudinally decoding the multiple malignant cellular
states that coexist within advanced, treatment-resistant tumors in individual patients.

The framework, undergirded by the company’s proprietary VIPER technology, licensed
by Columbia exclusively to DarwinHealth, is supported by pioneering research led
by DarwinHealth scientists Pasquale Laise, Mariano J. Alvarez, Andrea Califano, 
and their collaborators. Their single-cell systems biology studies, including the
just published **_Nature Genetics_** report, demonstrate that pancreatic cancers
comprise not one, but multiple, biologically distinct malignant cell states, each
governed by unique regulatory programs and therapeutic vulnerabilities. 

From a landscape-changing perspective, this is the first study to convincingly show
that vulnerabilities and desired drug responses among multiple cancer cell states
that coexist in an individual patient’s tumor (in this case, pancreatic cancer) 
are virtually identically conserved in patients with the same kind of cancer. In
other words, at the time of disease onset, all patients with a particular kind of
cancer—pancreatic cancer, glioblastoma, breast cancer, melanoma, prostate cancer,
and many others—harbor a recurring, predictable, and co-existing mix of multiple
cancer cell state abnormalities, all of which must be targeted relatively simultaneously
to achieve optimal treatment results.

By extension, enduring treatment responses—and most importantly, definitive cures—
especially for our most lethal and resistant tumors, will likely come, not from 
any single bullet, but from decoding the cancer cell states and then deploying multi-
drug combinations directed at each abnormal state early in the treatment course.
As the study shows, both decoding and targeting strategies can be systematically
identified using AI-based algorithms, such as those developed and commercialized
by DarwinHealth.

Together, the advances reported in _Nature Genetics_ establish the scientific foundations
and drug development roadmaps for a new generation of precision oncology treatments
based not simply on identifying genetic mutations, but on decoding the regulatory
architecture that determines how every malignant cell behaves—and how it can be 
therapeutically eliminated. Based on these recent results, as well as previous and
yet-to-come studies, these technologies developed and refined by DarwinHealth are
paving the way to more universal and more effective combination therapies for cancers
shown to be resistant to current treatments and, therefore, responsible for invariably
high mortality rates, frequently in excess of 90%.

**Beyond Precision Oncology**

For decades, precision oncology has largely defined tumors by their genomic mutations,
with therapies designed to inhibit individual oncogenic drivers. While this strategy
has produced important clinical advances, durable responses in highly resistant 
cancers such as pancreatic cancer and glioblastoma remain uncommon because tumors
continually evolve new, resistant cellular populations.

**Quantum Cancer Biology** proposes a fundamentally different view.

Rather than treating cancer as a single disease, the framework recognizes each tumor
as a dynamic ecosystem composed of multiple interacting malignant cell states. Each
cellular state is controlled by its own regulatory circuitry, possesses its own 
survival mechanisms, and exhibits its own therapeutic sensitivities.

The central challenge, therefore, is not simply identifying a mutation—it is identifying—
and in this case, using AI to decode—every clinically relevant cancer cell state
within an individual patient’s tumor and determining the optimal therapeutic strategy
for each.

DarwinHealth co-founder Califano has also recently published a review in the journal
_Cell_, "Fifteen challenges for generative AI applications to cell biology" ([https://www.cell.com/cell/fulltext/S0092-8674(26)00802-0](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4760010-1&h=1553038416&u=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674(26)00802-0&a=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674(26)00802-0)),
further illuminating the role of AI for network-based predictions to guide cancer
treatment.

**Making the Invisible Visible**

DarwinHealth’s drug discovery platform leverages single-cell transcriptomics, AI,
and regulatory network inference to infer master regulatory protein activity. The
company’s technology rigorously validates the functional reality and causality of
these cellular states through multi-modal integration with ATAC-seq, lineage tracing,
and CRISPR perturbations.

Unlike conventional gene-expression profiling—which merely catalogs transcript abundance—
DarwinHealth’s systems biology framework pinpoints the causal drivers maintaining
malignant states and identifies the molecular checkpoints most likely to collapse
them.

This approach transforms complex tumor landscapes into high-resolution functional
maps, revealing previously invisible targets for precision oncology.

**Pancreatic Cancer as the Prototype**

The power of this approach is illustrated by the original work just published in
_Nature Genetics. _

Using regulatory network analysis of single-cell transcriptomic data, the investigators
identified six highly conserved malignant pancreatic cancer cell states organized
into three developmental lineages. Importantly, these regulatory states proved remarkably
reproducible across independent patient cohorts, pancreatic cancer cell lines, and
patient-derived xenograft models, providing a robust mechanistic taxonomy of pancreatic
cancer heterogeneity. 

Rather than merely describing tumor diversity, the investigators identified the 
Master Regulator proteins responsible for maintaining each malignant state and experimentally
demonstrated that these regulatory programs represent therapeutically actionable
cellular dependencies. 

These findings provide a mechanistic roadmap for developing rational combination
therapies capable of simultaneously targeting multiple malignant populations within
a single tumor.

**Toward Rational Combination Therapy for Cancer**

Drug resistance remains the leading cause of mortality in patients with advanced
cancer.When one therapeutic agent successfully eliminates drug-sensitive cells, 
resistant populations frequently survive, expand, and ultimately repopulate the 
tumor.

Quantum Cancer Biology reframes this problem.

Instead of asking which single drug best treats a tumor, the framework asks:

Which combination of therapeutics is required to eliminate every biologically distinct
malignant cell state that exists within that patient’s cancer?

By computationally identifying these states and their regulatory dependencies, DarwinHealth
seeks to enable the rational design of multi-agent therapeutic strategies that address
the complete cellular architecture of resistant cancers, rather than only their 
dominant populations. This concept aligns with the company’s broader perspective
on treating tumors as complex "oncosystems." 

**Leadership Perspectives**

"The future of precision oncology lies in understanding the regulatory logic that
determines cellular identity—not merely cataloging mutations or measuring gene expression.
By reconstructing the regulatory networks that control individual cancer cell states,
we can identify the molecular mechanisms that sustain them and, ultimately, the 
therapeutic strategies capable of disrupting them."

**— Andrea Califano, Dr.**
**Co-Founder, DarwinHealth; President, New York Biohub;
Clyde and Helen Wu Professor of Chemical Systems Biology, Columbia University**

"Single-cell transcriptomics provides unprecedented resolution of tumor heterogeneity,
but understanding how those cellular states are established and maintained requires
systems-level analysis. By identifying the Master Regulator proteins controlling
each malignant state, we can move from describing tumor diversity to defining actionable
therapeutic vulnerabilities."

**— Pasquale Laise, PhD**
**Senior Director, Single-Cell Systems Pharmacology, DarwinHealth**

"For decades, oncology has searched for better drugs to treat individual cancers.
Quantum Cancer Biology begins with a different premise: that many advanced tumors
are not one cancer, but many biologically distinct cancers coexisting within the
same patient. Our mission is to decode those hidden cellular states and transform
that knowledge into rational—almost invariably, combination—therapeutic strategies
that target the full complement of regulatory network derangements."

**— Gideon Bosker, MD**
**Chief Executive Officer and Co-Founder, DarwinHealth**

**A New Framework for Precision Oncology**

DarwinHealth believes that Quantum Cancer Biology: A Cell-State Systems Biology 
Framework for Precision Oncology represents a foundational advance in cancer systems
biology.

By integrating single-cell transcriptomics, regulatory network inference, inferential
artificial intelligence, and systems pharmacology, the framework seeks to identify
the smallest rational combination of therapeutic interventions capable of targeting
the full spectrum of malignant cellular states within each patient’s tumor.

Initially developed and validated in pancreatic and brain cancer, the framework 
is now being extended across additional highly resistant malignancies—including 
glioblastoma and other aggressive solid tumors—with the goal of accelerating the
development of more effective precision combination therapies.

As oncology enters an era defined by cellular resolution rather than population 
averages, DarwinHealth believes Quantum Cancer Biology provides the conceptual and
computational foundation for decoding cancer’s hidden complexity—and translating
that knowledge into more durable therapeutic outcomes.

**About DarwinHealth**

Founded by **Gideon Bosker and Andrea Califano** in 2016, DarwinHealth is a New 
York City-based precision oncology company pioneering systems biology and artificial
intelligence technologies that decode regulatory mechanisms governing cancer. By
integrating regulatory network biology, single-cell analysis, and computational 
pharmacology, DarwinHealth develops predictive technologies to identify patient-
specific therapeutic vulnerabilities and accelerate the development of next-generation
precision cancer therapies.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [DarwinHealth Introduces Quantum Cancer Biology: A Cell-State Systems Biology Framework for Precision Oncology ](http://www.prnasia.com/story/archive/5034138_AE34138_0?rand=184833)